



May 9, 2024

Notice of Recording of Impairment Loss and Loss on Valuation of Financial Assets

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito; hereinafter “Santen”) announced that it recorded an impairment loss and loss on valuation of financial assets on intangible assets related to cell therapy products mainly composed of retinal progenitor cells in the fourth quarter (January 1, 2024 to March 31, 2024) of the fiscal year ended March 31, 2024.

1. Recording of impairment loss

Impairment loss amounted to JPY 6,994 million and loss on valuation of financial assets amounted to JPY 1,434 million. This is due to the review of the business plan related to cell therapy products mainly composed of retinal progenitor cells and because of reducing the book value of the intangible asset to the recoverable amount related to the item.

2. Impact of forecasts of consolidated financial results

The above impairment loss and loss on valuation of financial assets have been factored into the consolidated financial results for the fiscal year ended March 31, 2024, announced today.

Contact:

Guillaume Sakuma
Global Head of IR, IR Group
E-mail: ir@santen.com

About Santen

As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of “Happiness with Vision” by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, “*Tenki ni sanyo suru*,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen’s mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience “Happiness with Vision.”

For more information, please visit Santen’s website <https://www.santen.com/en>.